ID   AVR2B_HUMAN             Reviewed;         512 AA.
AC   Q13705; Q4VAV0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-MAY-2006, sequence version 3.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Activin receptor type-2B;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor type IIB;
DE            Short=ACTR-IIB;
DE   Flags: Precursor;
GN   Name=ACVR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8161782;
RA   Hilden K., Tuuri T., Eramaa M., Ritvos O.;
RT   "Expression of type II activin receptor genes during differentiation
RT   of human K562 cells and cDNA cloning of the human type IIB activin
RT   receptor.";
RL   Blood 83:2163-2170(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASP-459.
RX   PubMed=9621519; DOI=10.1007/s100380050054;
RA   Ishikawa S., Kai M., Murata Y., Tamari M., Daigo Y., Murano T.,
RA   Ogawa M., Nakamura Y.;
RT   "Genomic organization and mapping of the human activin receptor type
RT   IIB (hActR-IIB) gene.";
RL   J. Hum. Genet. 43:132-134(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS
RP   HTX4 HIS-40 AND ILE-494.
RX   PubMed=9916847;
RX   DOI=10.1002/(SICI)1096-8628(19990101)82:1<70::AID-AJMG14>3.0.CO;2-Y;
RA   Kosaki R., Gebbia M., Kosaki K., Lewin M., Bowers P., Towbin J.A.,
RA   Casey B.;
RT   "Left-right axis malformations associated with mutations in ACVR2B,
RT   the gene for human activin receptor type IIB.";
RL   Am. J. Med. Genet. 82:70-76(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION, INTERACTION WITH ACVR1B, AND FUNCTION IN
RP   PHOSPHORYLATION OF ACVR1B.
RX   PubMed=8622651; DOI=10.1128/MCB.16.3.1066;
RA   Attisano L., Wrana J.L., Montalvo E., Massague J.;
RT   "Activation of signalling by the activin receptor complex.";
RL   Mol. Cell. Biol. 16:1066-1073(1996).
RN   [6]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M.,
RA   Karpova T.S., McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (3.36 ANGSTROMS) OF 19-134 IN COMPLEX WITH
RP   ACVRL1 AND BMP9, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-42 AND
RP   ASN-65.
RX   PubMed=22718755; DOI=10.1074/jbc.M112.377960;
RA   Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D.,
RA   Liu J., Ucran J.A., Liharska K., Underwood K.W., Seehra J., Kumar R.,
RA   Grinberg A.V.;
RT   "Specificity and structure of a high affinity activin receptor-like
RT   kinase 1 (ALK1) signaling complex.";
RL   J. Biol. Chem. 287:27313-27325(2012).
RN   [8]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-176.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase activin type-2
CC       receptor forming an activin receptor complex with activin type-1
CC       serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).
CC       Transduces the activin signal from the cell surface to the
CC       cytoplasm and is thus regulating many physiological and
CC       pathological processes including neuronal differentiation and
CC       neuronal survival, hair follicle development and cycling, FSH
CC       production by the pituitary gland, wound healing, extracellular
CC       matrix production, immunosuppression and carcinogenesis. Activin
CC       is also thought to have a paracrine or autocrine role in
CC       follicular development in the ovary. Within the receptor complex,
CC       the type-2 receptors act as a primary activin receptors (binds
CC       activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA).
CC       The type-1 receptors like ACVR1B act as downstream transducers of
CC       activin signals. Activin binds to type-2 receptor at the plasma
CC       membrane and activates its serine-threonine kinase. The activated
CC       receptor type-2 then phosphorylates and activates the type-1
CC       receptor. Once activated, the type-1 receptor binds and
CC       phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine
CC       residues of the C-terminal tail. Soon after their association with
CC       the activin receptor and subsequent phosphorylation, SMAD2 and
CC       SMAD3 are released into the cytoplasm where they interact with the
CC       common partner SMAD4. This SMAD complex translocates into the
CC       nucleus where it mediates activin-induced transcription.
CC       Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can
CC       prevent the association of SMAD2 and SMAD3 with the activin
CC       receptor complex, thereby blocking the activin signal. Activin
CC       signal transduction is also antagonized by the binding to the
CC       receptor of inhibin-B via the IGSF1 inhibin coreceptor.
CC       {ECO:0000269|PubMed:8622651}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Forms an activin receptor complex with activin type II
CC       receptors such as ACVR1B. Interacts with VPS39. Interacts with
CC       DYNLT1. {ECO:0000250|UniProtKB:P27040,
CC       ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:22718755,
CC       ECO:0000269|PubMed:8622651}.
CC   -!- INTERACTION:
CC       O14793:MSTN; NbExp=4; IntAct=EBI-1383577, EBI-8542977;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=ActR-IIB2;
CC         IsoId=Q13705-1; Sequence=Displayed;
CC       Name=ActR-IIB1;
CC         IsoId=Q13705-2; Sequence=Not described;
CC         Note=Produced from the insertion in the transcript of 82 base
CC         pairs, leading to frameshift and protein truncation. May be not
CC         functional.;
CC   -!- PTM: Phosphorylated. Constitutive phosphorylation is in part
CC       catalyzed by its own kinase activity.
CC       {ECO:0000269|PubMed:8622651}.
CC   -!- DISEASE: Heterotaxy, visceral, 4, autosomal (HTX4) [MIM:613751]: A
CC       form of visceral heterotaxy, a complex disorder due to disruption
CC       of the normal left-right asymmetry of the thoracoabdominal organs.
CC       Visceral heterotaxy or situs ambiguus results in randomization of
CC       the placement of visceral organs, including the heart, lungs,
CC       liver, spleen, and stomach. The organs are oriented randomly with
CC       respect to the left-right axis and with respect to one another. It
CC       can been associated with variety of congenital defects including
CC       cardiac malformations. HTX4 clinical features include
CC       dextrocardia, right aortic arch and a right-sided spleen,
CC       anomalies of the inferior and the superior vena cava, atrial
CC       ventricular canal defect with dextro-transposed great arteries,
CC       pulmonary stenosis, polysplenia and midline liver.
CC       {ECO:0000269|PubMed:9916847}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77533; CAA54671.1; -; mRNA.
DR   EMBL; AB008681; BAA24180.2; -; Genomic_DNA.
DR   EMBL; AF060202; AAC64515.1; -; Genomic_DNA.
DR   EMBL; AF060199; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; AF060200; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; AF060201; AAC64515.1; JOINED; Genomic_DNA.
DR   EMBL; BC096243; AAH96243.1; -; mRNA.
DR   EMBL; BC096244; AAH96244.1; -; mRNA.
DR   EMBL; BC099642; AAH99642.1; -; mRNA.
DR   CCDS; CCDS2679.1; -. [Q13705-1]
DR   PIR; I37134; I37134.
DR   RefSeq; NP_001097.2; NM_001106.3. [Q13705-1]
DR   UniGene; Hs.174273; -.
DR   PDB; 2H62; X-ray; 1.85 A; D=19-116.
DR   PDB; 2QLU; X-ray; 2.00 A; A=190-487.
DR   PDB; 4FAO; X-ray; 3.36 A; E/F/K/L/Q/R/W/X/e/f/k/l=19-134.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2QLU; -.
DR   PDBsum; 4FAO; -.
DR   ProteinModelPortal; Q13705; -.
DR   SMR; Q13705; -.
DR   BioGrid; 106608; 47.
DR   IntAct; Q13705; 6.
DR   MINT; MINT-3028545; -.
DR   STRING; 9606.ENSP00000340361; -.
DR   BindingDB; Q13705; -.
DR   ChEMBL; CHEMBL5466; -.
DR   GuidetoPHARMACOLOGY; 1792; -.
DR   iPTMnet; Q13705; -.
DR   PhosphoSitePlus; Q13705; -.
DR   BioMuta; ACVR2B; -.
DR   DMDM; 97535735; -.
DR   EPD; Q13705; -.
DR   PaxDb; Q13705; -.
DR   PeptideAtlas; Q13705; -.
DR   PRIDE; Q13705; -.
DR   DNASU; 93; -.
DR   Ensembl; ENST00000352511; ENSP00000340361; ENSG00000114739. [Q13705-1]
DR   GeneID; 93; -.
DR   KEGG; hsa:93; -.
DR   UCSC; uc003cif.4; human. [Q13705-1]
DR   CTD; 93; -.
DR   DisGeNET; 93; -.
DR   GeneCards; ACVR2B; -.
DR   HGNC; HGNC:174; ACVR2B.
DR   HPA; CAB025115; -.
DR   HPA; HPA007398; -.
DR   MalaCards; ACVR2B; -.
DR   MIM; 602730; gene.
DR   MIM; 613751; phenotype.
DR   neXtProt; NX_Q13705; -.
DR   OpenTargets; ENSG00000114739; -.
DR   Orphanet; 157769; Situs ambiguus.
DR   PharmGKB; PA24495; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; Q13705; -.
DR   KO; K13596; -.
DR   OMA; ILLAFWM; -.
DR   OrthoDB; EOG091G03YO; -.
DR   PhylomeDB; Q13705; -.
DR   TreeFam; TF352876; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1433617; Regulation of signaling by NODAL.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q13705; -.
DR   SIGNOR; Q13705; -.
DR   ChiTaRS; ACVR2B; human.
DR   EvolutionaryTrace; Q13705; -.
DR   GeneWiki; ACVR2B; -.
DR   GenomeRNAi; 93; -.
DR   PRO; PR:Q13705; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114739; -.
DR   CleanEx; HS_ACVR2B; -.
DR   Genevisible; Q13705; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; IPI:BHF-UCL.
DR   GO; GO:0048185; F:activin binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:HGNC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:HGNC.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0032147; P:activation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:HGNC.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0030073; P:insulin secretion; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007498; P:mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IGI:BHF-UCL.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0035265; P:organ growth; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0031016; P:pancreas development; IEA:Ensembl.
DR   GO; GO:0032927; P:positive regulation of activin receptor signaling pathway; IDA:HGNC.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Heterotaxy; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    512       Activin receptor type-2B.
FT                                /FTId=PRO_0000024404.
FT   TOPO_DOM     19    137       Extracellular. {ECO:0000255}.
FT   TRANSMEM    138    158       Helical. {ECO:0000255}.
FT   TOPO_DOM    159    512       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      190    480       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     196    204       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      491    512       Interaction with DYNLT1.
FT                                {ECO:0000250|UniProtKB:P27040}.
FT   ACT_SITE    321    321       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     217    217       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22718755}.
FT   CARBOHYD     65     65       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22718755}.
FT   DISULFID     29     59       {ECO:0000269|PubMed:22718755}.
FT   DISULFID     49     77       {ECO:0000269|PubMed:22718755}.
FT   DISULFID     84    103       {ECO:0000269|PubMed:22718755}.
FT   DISULFID     90    102       {ECO:0000269|PubMed:22718755}.
FT   DISULFID    104    109       {ECO:0000269|PubMed:22718755}.
FT   VARIANT      40     40       R -> H (in HTX4; dbSNP:rs121434437).
FT                                {ECO:0000269|PubMed:9916847}.
FT                                /FTId=VAR_013281.
FT   VARIANT     176    176       P -> R (in dbSNP:rs35882617).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041396.
FT   VARIANT     459    459       E -> D (in dbSNP:rs500611).
FT                                {ECO:0000269|PubMed:9621519}.
FT                                /FTId=VAR_050594.
FT   VARIANT     494    494       V -> I (in HTX4; dbSNP:rs121434438).
FT                                {ECO:0000269|PubMed:9916847}.
FT                                /FTId=VAR_013282.
FT   CONFLICT     16     17       CA -> WP (in Ref. 1; CAA54671).
FT                                {ECO:0000305}.
FT   CONFLICT     64     64       R -> A (in Ref. 1 and 2). {ECO:0000305}.
FT   CONFLICT    459    459       E -> A (in Ref. 3; AAC64515).
FT                                {ECO:0000305}.
FT   STRAND       27     33       {ECO:0000244|PDB:2H62}.
FT   HELIX        36     39       {ECO:0000244|PDB:2H62}.
FT   STRAND       43     49       {ECO:0000244|PDB:2H62}.
FT   STRAND       57     66       {ECO:0000244|PDB:2H62}.
FT   STRAND       69     79       {ECO:0000244|PDB:2H62}.
FT   HELIX        82     84       {ECO:0000244|PDB:2H62}.
FT   STRAND       88     91       {ECO:0000244|PDB:2H62}.
FT   STRAND       98    106       {ECO:0000244|PDB:2H62}.
FT   TURN        107    110       {ECO:0000244|PDB:2H62}.
FT   STRAND      111    114       {ECO:0000244|PDB:2H62}.
FT   STRAND      191    197       {ECO:0000244|PDB:2QLU}.
FT   STRAND      200    209       {ECO:0000244|PDB:2QLU}.
FT   STRAND      212    219       {ECO:0000244|PDB:2QLU}.
FT   HELIX       221    223       {ECO:0000244|PDB:2QLU}.
FT   HELIX       224    235       {ECO:0000244|PDB:2QLU}.
FT   STRAND      247    253       {ECO:0000244|PDB:2QLU}.
FT   TURN        256    258       {ECO:0000244|PDB:2QLU}.
FT   STRAND      260    266       {ECO:0000244|PDB:2QLU}.
FT   HELIX       273    279       {ECO:0000244|PDB:2QLU}.
FT   HELIX       284    302       {ECO:0000244|PDB:2QLU}.
FT   STRAND      305    308       {ECO:0000244|PDB:2QLU}.
FT   TURN        309    311       {ECO:0000244|PDB:2QLU}.
FT   STRAND      312    314       {ECO:0000244|PDB:2QLU}.
FT   STRAND      316    318       {ECO:0000244|PDB:2QLU}.
FT   HELIX       324    326       {ECO:0000244|PDB:2QLU}.
FT   STRAND      327    329       {ECO:0000244|PDB:2QLU}.
FT   STRAND      335    337       {ECO:0000244|PDB:2QLU}.
FT   STRAND      344    346       {ECO:0000244|PDB:2QLU}.
FT   HELIX       362    364       {ECO:0000244|PDB:2QLU}.
FT   HELIX       367    370       {ECO:0000244|PDB:2QLU}.
FT   HELIX       378    398       {ECO:0000244|PDB:2QLU}.
FT   TURN        413    417       {ECO:0000244|PDB:2QLU}.
FT   HELIX       424    431       {ECO:0000244|PDB:2QLU}.
FT   HELIX       442    446       {ECO:0000244|PDB:2QLU}.
FT   HELIX       448    460       {ECO:0000244|PDB:2QLU}.
FT   HELIX       465    467       {ECO:0000244|PDB:2QLU}.
FT   HELIX       471    482       {ECO:0000244|PDB:2QLU}.
SQ   SEQUENCE   512 AA;  57724 MW;  B377FEF92EF74937 CRC64;
     MTAPWVALAL LWGSLCAGSG RGEAETRECI YYNANWELER TNQSGLERCE GEQDKRLHCY
     ASWRNSSGTI ELVKKGCWLD DFNCYDRQEC VATEENPQVY FCCCEGNFCN ERFTHLPEAG
     GPEVTYEPPP TAPTLLTVLA YSLLPIGGLS LIVLLAFWMY RHRKPPYGHV DIHEDPGPPP
     PSPLVGLKPL QLLEIKARGR FGCVWKAQLM NDFVAVKIFP LQDKQSWQSE REIFSTPGMK
     HENLLQFIAA EKRGSNLEVE LWLITAFHDK GSLTDYLKGN IITWNELCHV AETMSRGLSY
     LHEDVPWCRG EGHKPSIAHR DFKSKNVLLK SDLTAVLADF GLAVRFEPGK PPGDTHGQVG
     TRRYMAPEVL EGAINFQRDA FLRIDMYAMG LVLWELVSRC KAADGPVDEY MLPFEEEIGQ
     HPSLEELQEV VVHKKMRPTI KDHWLKHPGL AQLCVTIEEC WDHDAEARLS AGCVEERVSL
     IRRSVNGTTS DCLVSLVTSV TNVDLPPKES SI
//
